1,591 top medical experts on Neuroendocrine Tumors across 46 countries and 41 U.S. states, including 1,526 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants.

  1. Neuroendocrine Tumors: Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via apud cells), the presence of tumor-associated antigens, and isozyme composition.
  2. Clinical guidelines are the recommended starting point to understand initial steps and current protocols in any disease or procedure:
  3. Broader Categories (#Experts): Neuroectodermal Tumors (593) and Narrower Categories: Acidophil Adenoma (7), Apudoma (15), Basophil Adenoma (4), Carcinoid Tumor (2,100), Chromophobe Adenoma (15), Melanoma (5,253), Neurilemmoma (2,127), Neuroendocrine Carcinoma (2,955), Paraganglioma (2,123).
  4. Clinical Trials ClinicalTrials.gov : at least 557 including 57 Active, 181 Completed, 152 Recruiting


  

        

                    


    These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads, screen scraping or using the data) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

  1. Strosberg, Jonathan Raphael   Medical Oncology   ClinicalTrials.gov Google Publications
    Moffitt Cancer Center, Tampa, FL, USA. Electronic address: .
    Physician  Highly Cited  Highly Published  Guideline  Clinical Trial  Case Reports  Review 
    Medical school: Js Weill Medical College, Cornell University (MD, 1999)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 81/100
    Disclosed payments in 2021 from 20 biomedical companies, totalling $28,478.94, including $14,234.67 from  Ipsen Biopharmaceuticals, Inc
    Subjects: Pancreatic Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Octreotide; Stomach Neoplasms
    Categories: Drug Therapy; Therapeutic Use; Therapy; Pathology; Analogs & Derivatives; Diagnosis
    Phase 3 Trial of (2017)
    Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. (2016)

  2. Yao, James C   Medical Oncology   ClinicalTrials.gov Google Publications
    Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Physician  Highly Cited  Highly Published  Guideline  Clinical Trial 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 68/100
    Disclosed payments in 2021 from 6 biomedical companies, totalling $12,806.66, including $6,600 from  Chiasma, Inc.
    Subjects: Pancreatic Neoplasms; Gastrointestinal Neoplasms; Antineoplastic Agents; Everolimus; Octreotide
    Categories: Drug Therapy; Therapeutic Use; Therapy; Metabolism; Blood; Pathology
    Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. (2017)
    Everolimus for advanced pancreatic neuroendocrine tumors. (2011)

  3. Wolin, Edward M   Medical Oncology   Google Publications
    Icahn School of Medicine at Mount Sinai, New York, NY, USA. Top Hospital
    Physician  Highly Cited  Highly Published  Guideline  Clinical Trial  Case Reports  Review 
    Medical school: Yale University School of Medicine (MD, 1974)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 72.4/100
    Disclosed payments from biomedical company (Chiasma, Inc.) in 2021 for $400
    Subjects: Pancreatic Neoplasms; Antineoplastic Agents; Gastrointestinal Neoplasms; Octreotide; Somatostatin
    Categories: Drug Therapy; Therapeutic Use; Analogs & Derivatives; Pathology; Therapy; Administration & Dosage
    Phase 3 Trial of (2017)
    Everolimus for advanced pancreatic neuroendocrine tumors. (2011)

  4. Klimstra, David S   Anatomic Pathology   Google Publications
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
    Physician  Highly Cited  Highly Published  Guideline 
    Subjects: Pancreatic Neoplasms; Biomarkers, Tumor; Intestinal Neoplasms; Gastrointestinal Neoplasms; Stomach Neoplasms
    Categories: Pathology; Classification; Genetics; Diagnosis; Surgery; Metabolism
    A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. (2018)
    DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. (2011)

  5. Kulke, Matthew Helmut     ClinicalTrials.gov Google Publications
    Section of Hematology and Oncology, Boston University and Boston Medical Center, Boston, MA.
    Physician  Highly Cited  Highly Published  Guideline  Clinical Trial  Case Reports 
    Subjects: Pancreatic Neoplasms; Intestinal Neoplasms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Gastrointestinal Neoplasms
    Categories: Drug Therapy; Therapeutic Use; Therapy; Genetics; Pathology; Administration & Dosage
    Phase 3 Trial of (2017)
    Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. (2016)

  6. Kunz, Pamela L   Medical Oncology   ClinicalTrials.gov Google Publications
    Yale School of Medicine, New Haven, CT, USA.
    Physician  Highly Cited  Highly Published  Guideline  Clinical Trial  Case Reports 
    Medical school: Geisel School of Medicine at Dartmouth (MD, 2001)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 65/100
    Disclosed payments in 2021 from 5 biomedical companies, totalling $7,636.34, including $3,100 from  Ipsen Biopharmaceuticals, Inc
    Subjects: Pancreatic Neoplasms; Octreotide; Organometallic Compounds; Intestinal Neoplasms; Receptors, Peptide
    Categories: Therapy; Pathology; Drug Therapy; Therapeutic Use; Analogs & Derivatives; Diagnosis
    Phase 3 Trial of (2017)
    Consensus guidelines for the management and treatment of neuroendocrine tumors. (2013)

  7. Hobday, Timothy J   Medical Oncology   ClinicalTrials.gov Google Publications
    Division of Oncology, Department of Medicine, Mayo Clinic, Rochester, MN. Top Hospital
    Physician  Highly Cited  Clinical Trial 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 79.7/100
    Subjects: Pancreatic Neoplasms; Antineoplastic Agents; Octreotide; Antineoplastic Combined Chemotherapy Protocols; Sirolimus
    Categories: Drug Therapy; Therapeutic Use; Pathology; Analogs & Derivatives; Adverse Effects; Administration & Dosage
    Phase 3 Trial of (2017)
    Everolimus for advanced pancreatic neuroendocrine tumors. (2011)

  8. Modlin, Irvin M   Surgery   Google Publications
    Yale University School of Medicine, New Haven, CT. Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports  Review 
    Subjects: Biomarkers, Tumor; Pancreatic Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Stomach Neoplasms
    Categories: Blood; Genetics; Diagnosis; Metabolism; Pathology; Therapy
    The epidemiology of gastroenteropancreatic neuroendocrine tumors. (2011)
    Recommendations for management of patients with neuroendocrine liver metastases. (2014)

  9. Shah, Manisha H   Medical Oncology   ClinicalTrials.gov Google Publications
    The Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute, Columbus, OH. Top Hospital
    Physician  Highly Cited  Guideline  Clinical Trial 
    Medical school: Other (MD, 1990)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 82.3/100
    Subjects: Pancreatic Neoplasms; Liver Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Agents; Chemoembolization, Therapeutic
    Categories: Drug Therapy; Therapy; Therapeutic Use; Administration & Dosage; Secondary; Antagonists & Inhibitors
    Everolimus for advanced pancreatic neuroendocrine tumors. (2011)
    NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. (2018)

  10. Benson, Al B   Medical Oncology  Google Publications
    Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL. Top Hospital
    Physician  Highly Cited  Guideline  Clinical Trial 
    Medical school: State University of New York at Buffalo School of Medicine (MD, 1976)
    Medicare Accepted
    Disclosed payments in 2021 from 7 biomedical companies, totalling $14,945, including $5,805 from  E.R. Squibb & Sons, L.L.C.
    Subjects: Gastrointestinal Neoplasms; Octreotide; Liver Neoplasms; Pancreatic Neoplasms; Antineoplastic Agents
    Categories: Drug Therapy; Statistics & Numerical Data; Therapeutic Use; Therapy; Diagnosis; Radiotherapy
    Phase 3 Trial of (2017)
    NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. (2018)

  11. Halperin, Daniel M   Medical Oncology   ClinicalTrials.gov Google Publications
    Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston.
    Physician  Highly Cited  Highly Published  Guideline  Clinical Trial 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 68/100
    Disclosed payments in 2021 from 9 biomedical companies, totalling $12,892.83, including $9,603 from  TerSera Therapeutics LLC
    Subjects: Pancreatic Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Gastrointestinal Neoplasms; Biomarkers, Tumor; Diarrhea
    Categories: Drug Therapy; Therapy; Therapeutic Use; Diagnosis; Prevention & Control; Epidemiology
    Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. (2017)
    NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. (2018)

  12. Bushnell, David L   Nuclear Medicine   ClinicalTrials.gov Google Publications
    Division of Nuclear Medicine, Department of Radiology, University of Iowa Hospital and Clinics, Iowa City, Iowa; . Top Hospital
    Physician  Highly Cited  Guideline  Clinical Trial 
    Subjects: Octreotide; Organometallic Compounds; Gastrointestinal Neoplasms; Pancreatic Neoplasms; Radiopharmaceuticals
    Categories: Therapeutic Use; Radiotherapy; Analogs & Derivatives; Diagnosis; Diagnostic Imaging; Drug Therapy
    Phase 3 Trial of (2017)
    Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With (2018)

  13. Berlin, Jordan D   Medical Oncology  ClinicalTrials.gov Google Publications
    Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. Top Hospital
    Physician  Highly Cited  Guideline  Clinical Trial 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 73.2/100
    Disclosed payments in 2021 from 13 biomedical companies, totalling $18,462, including $5,950 from  Insmed, Inc.
    Subjects: Intestinal Neoplasms; Stomach Neoplasms; Biomarkers, Tumor; Pancreatic Neoplasms; Colonic Neoplasms
    Categories: Pathology; Therapy; Secondary; Diagnostic Imaging; Therapeutic Use; Genetics
    Phase 3 Trial of (2017)
    NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. (2018)

  14. Tang, Laura H   Anatomic Pathology   Google Publications
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Medical school: Other (MD, 1983)
    Medicare Accepted
    Subjects: Pancreatic Neoplasms; Intestinal Neoplasms; Liver Neoplasms; Biomarkers, Tumor; Stomach Neoplasms
    Categories: Pathology; Metabolism; Genetics; Surgery; Classification; Chemistry
    DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. (2011)
    The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. (2015)

  15. Bergsland, Emily K   Internal Medicine   ClinicalTrials.gov Google Publications
    Department of Clinical Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, 94158, United States. Top Hospital
    Physician  Highly Cited  Highly Published  Guideline  Clinical Trial  Case Reports  Review 
    Subjects: Pancreatic Neoplasms; Intestinal Neoplasms; Liver Neoplasms; Lymph Nodes; Ileal Neoplasms
    Categories: Therapy; Surgery; Pathology; Therapeutic Use; Drug Therapy; Diagnosis
    NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. (2018)
    Neuroendocrine tumors, version 1.2015. (2015)

  16. Howe, James R   Surgical Oncology   Google Publications
    Division of Surgical Oncology and Endocrine Surgery, Department of Surgery, University of Iowa Carver College of Medicine, Iowa City, IA. Top Hospital
    Physician  Highly Cited  Highly Published  Guideline  Clinical Trial  Case Reports 
    Subjects: Pancreatic Neoplasms; Intestinal Neoplasms; Liver Neoplasms; Biomarkers, Tumor; Stomach Neoplasms
    Categories: Pathology; Genetics; Metabolism; Therapy; Surgery; Diagnostic Imaging
    The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. (2020)
    The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. (2013)

  17. Bodei, Lisa     ClinicalTrials.gov Google Publications
    Memorial Sloan Kettering Cancer Center, New York, NY, USA. Top Hospital
    Physician  Highly Cited  Highly Published  Guideline  Clinical Trial  Case Reports  Review 
    Subjects: Octreotide; Biomarkers, Tumor; Radiopharmaceuticals; Organometallic Compounds; Pancreatic Neoplasms
    Categories: Therapeutic Use; Blood; Diagnosis; Radiotherapy; Diagnostic Imaging; Analogs & Derivatives
    The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. (2013)
    Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. (2021)

  18. Hendifar, Andrew E   Hematology & Oncology   ClinicalTrials.gov Google Publications
    Cedars-Sinai Medical Center, Los Angeles, CA, USA.
    Physician  Highly Cited  Clinical Trial  Case Reports  Review 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 63/100
    Disclosed payments in 2021 from 7 biomedical companies, totalling $21,000, including $8,750 from  Novartis Pharmaceuticals Corporation
    Subjects: Octreotide; Organometallic Compounds; Intestinal Neoplasms; Intestine, Small; Lung Neoplasms
    Categories: Pathology; Mortality; Therapeutic Use; Methods; Surgery; Drug Therapy
    Phase 3 Trial of (2017)
    Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With (2018)

  19. Beltran, Himisha   Medical Oncology   Google Publications
    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Top Hospital
    Physician  Highly Cited  Case Reports 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 66/100
    Disclosed payments in 2021 from 9 biomedical companies, totalling $19,417, including $5,040 from  PFIZER INC.
    Subjects: Prostatic Neoplasms; Adenocarcinoma; Gene Expression Regulation, Neoplastic; Prostatic Neoplasms, Castration-Resistant; Neoplasms, Second Primary
    Categories: Genetics; Metabolism; Diagnosis; Pathology; Drug Therapy; Therapeutic Use
    Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. (2016)
    Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. (2011)

  20. Asa, Sylvia L   Anatomic Pathology   Google Publications
    Department of Pathology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland Ohio, 44106, USA. . Top Hospital
    Physician  Highly Cited  Highly Published  Guideline  Case Reports  Review 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 88/100
    Disclosed payments in 2021 from 4 biomedical companies, totalling $1,312.5, including $1,312.5 from  LEICA MICROSYSTEMS INC.
    Subjects: Pituitary Neoplasms; Pancreatic Neoplasms; Biomarkers, Tumor; Gastrointestinal Neoplasms; Intestinal Neoplasms
    Categories: Pathology; Genetics; Metabolism; Classification; Diagnosis; Therapy
    A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. (2018)
    From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. (2017)

Note:
  1. Only the top 20 experts are shown. You may filter your results or use the geolocation tabs. Contact us to purchase the entire list.
These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads or screen scraping) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

);